Law360, New York (September 28, 2012, 5:51 PM ET) -- A Georgia federal judge on Friday dismissed antitrust allegations that Solvay Pharmaceuticals Inc. filed sham patent infringement litigation against generic rivals in order to delay the entry of competing versions of Androgel from the market through a reverse payment settlement.
U.S. District Judge Thomas W. Thrash granted the defendants — Solvay and generics makers Par Pharmaceutical Cos. Inc., Paddock Laboratories Inc. and Watson Pharmaceuticals Inc. — summary judgment on the private plaintiffs' remaining claims in the antitrust case, originally instigated by a Federal Trade Commission investigation....
Sham Litigation Claims Nixed In Androgel Pay-For-Delay MDL
To view the full article, take a free trial now.
